International Scholarly Research Notices / 2012 / Article / Tab 3

Research Article

Doripenem Dosing Recommendations for Critically Ill Patients Receiving Continuous Renal Replacement Therapy

Table 3

Probability of pharmacokinetic/pharmacodynamic target (fT > MIC ≥ 35%) attainment by CVVHDF flow rate in acute kidney impairment subjects.

MIC (mg/L)CVVHDF flow rate (L/hr)
1.251.752.252.52.753.253.53.754.5

Anephric subjectsa (250 mg q12h, 4-hour infusion)

10.9850.9810.9780.9750.9730.9680.9660.9630.954
20.5780.5470.5140.5000.4820.4520.4390.4240.379
40.0170.0140.0110.0100.0090.0080.0060.0060.005
80.0000.0000.0000.0000.0000.0000.0000.0000.000

Subjects with residual kidney functionb (500 mg q12h, 4-hour infusion)

10.9990.9990.9990.9980.9980.9980.9980.9980.998
20.9520.9440.9370.9330.9290.9190.9140.9110.896
40.3670.3450.3230.3110.30.2790.2690.2590.231
80.0050.0030.0030.0020.0020.0020.0020.0010.001

a Pharmacokinetic/pharmacodynamic target attainment probabilities for CVVHDF are based on a simulation of 5000 anephric subjects using mean pharmacokinetic parameter estimates from Cirillo et al. [14] with inflated between-subject variability (40% CV) and assuming a protein binding of 8.5%. Total CL represented the sum of 2 × CLNR and CVVHDF clearance.
b The renal component of the clearance allowed residual kidney function with a CrCL of 30 mL/min.